Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

  • Publication # 13-RA006

Sulfonylurea medication linked to kidney function decline among patients with diabetes

Chronic Disease

People with type 2 diabetes are at increased risk for end-stage kidney disease. In fact, diabetes accounts for 45 percent of all cases. People with diabetes may take a variety of oral medications to control their diabetes. A new study concludes that individuals taking the class of diabetes drugs known as sulfonylureas increase their risk for kidney function decline compared to patients using metformin or rosiglitazone. The study included 93,577 patients who received care from the Veterans Administration between 2001 and 2008. All had filled a prescription for an oral diabetes drug: 65 percent for metformin, 33 percent for a sulfonylurea, and 2 percent for rosiglitazone. The primary outcome looked at was a persistent decline in estimated glomerular filtration rate (eGFR), a measure of kidney function of 25 percent or more (eGFR event), or a diagnosis of end-stage renal disease (ESRD). The secondary outcome was an eGFR event, ESRD, or death.

All-cause mortality rates were highest for patients taking sulfonylureas and lowest for rosiglitazone. Compared to metformin users, those taking sulfonylureas had a 20 percent increased risk of an eGFR event, developing ESRD, or death. These findings support national and international recommendations that metformin be used as a first-line therapy for patients with type 2 diabetes in the early stages of kidney disease. The study was supported in part by the Agency for Healthcare Research and Quality (Contract No. 290-05-0042).

See "Comparative effectiveness of incident oral antidiabetic drugs on kidney function," by Adrian M. Hung, M.D., Christianne L. Roumie, M.D., Robert A. Greevy, Ph.D., and others in Kidney International 81, pp. 698-706, 2012.

KB

Page last reviewed March 2013
Internet Citation: Sulfonylurea medication linked to kidney function decline among patients with diabetes: Chronic Disease. March 2013. Agency for Healthcare Research and Quality, Rockville, MD. https://archive.ahrq.gov/news/newsletters/research-activities/13mar/0313RA7.html

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care